Canopy Growth Corporation Q3 2026 Earnings Recap

WEED.TO Q3 2026 February 6, 2026

Canopy Growth demonstrated solid financial progress in Q3 FY2026, achieving its narrowest adjusted EBITDA loss to date while simultaneously enhancing its balance sheet and operational efficiency. The company is well-positioned for future growth, particularly in medical cannabis and international markets.

Earnings Per Share Miss

$-0.18 vs $-0.06 est.

-218.6% surprise

Revenue Beat

74541000 vs 70847850 est.

+5.2% surprise

Market Reaction

1-Day -0.66%

5-Day -5.92%

30-Day -3.95%

Key Takeaways

Adjusted EBITDA loss narrowed significantly, reflecting ongoing cost discipline and improved execution.
Canadian medical revenue increased by 15% year-over-year, marking the sixth consecutive quarter of growth.
The planned acquisition of MTL Cannabis aims to strengthen Canopy's leadership in Canadian medical cannabis and expand its presence in Quebec's adult-use market.
Net revenue from international operations increased by 22% sequentially, indicating positive momentum in global markets.
A recapitalization effort successfully bolstered liquidity, extending debt maturities to 2031 and enhancing financial flexibility.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit WEED.TO on AllInvestView.